公司资料
Bone Biologics 股价、新闻与催化剂
- 股票代码:
- BBLG
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.47 USD (-3.77%)
收盘价
最后更新: 2026年10月8日
2.28M USD
市值
股价为何变动
截至 2026年10月8日，BBLG 下跌 3.77%，收于 $0.4691。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Orthobiologic Product Developer
Bone Biologics develops biologic products intended to improve bone formation in spinal fusion. Its lead candidate combines a recombinant growth factor with a commonly used bone-graft material.
NB1 Bone Graft Candidate
NB1 combines recombinant human NELL-1 protein with demineralized bone matrix. NELL-1 is intended to promote targeted bone formation while the matrix provides a scaffold for new tissue growth.
Lumbar Fusion Pilot Study
The first-in-human clinical study is evaluating NB1 in patients undergoing transforaminal lumbar interbody fusion for degenerative disc disease. The trial compares the product's safety and fusion performance with standard grafting approaches.
Pivotal Development Path
The pilot design was reviewed with the FDA and is intended to inform a later U.S. pivotal study. Clinical evidence from Australia will help determine sample size, endpoints, and the broader regulatory strategy.
Manufacturing and Product Stability
Bone Biologics is developing manufacturing, quality, and storage processes for recombinant NELL-1. Extending validated shelf life improves the practicality of supplying clinical sites and future commercial customers.
未来催化剂
- Completion of enrollment in the first-in-human NB1 pilot study by the end of 2026.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。